HER2 becomes a novel survival biomarker for gastric cancer patients: a pooled analysis.

ABSTRACT:

Background

Although anti-HER2 therapies have been widely used against gastric carcinoma, the prognostic significance of HER2 overexpression remains unclear. Previous studies failed to provide convincible evidence due to inconsistent HER2 evaluation criteria and heterogeneous clinical characteristics.

Objectives

To figure out the prognostic significance of HER2 expression in gastric cancer, we rigorously designed and conducted this study.

Design

Meta-analysis.

Data sources and methods

Record retrieval was performed by searching PubMed, Web of Science, Cochrane Library, Embase, ASCO, and ESMO meeting libraries from inception to November 2022. Cohort studies investigating overall survival comparison between HER2-positive and HER2-negative gastric cancer patients w

SUBMITTER: Cheng J 

PROVIDER: S-EPMC11401144 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature